Three decades of glucose-lowering therapy in patients at high cardiovascular risk – A real-world analysis
Neyer M, Vogel JB, Elsner P, et al.
Diabetes Obes Metab. Pub. online 27 Nov 2024.
Leggi
Breaking news
High-protein vegan and omnivorous diets improve peripheral insulin sensitivity to a similar extent in people with type 2 diabetes
Whelehan G, Dirks ML, West S, et al.
Diabetes Obes Metab. Pub. online 27 Nov 2024.
Leggi
Managing diabetic chronic kidney disease in pregnancy: current clinical practice and uncertainties
Banerjee A, Brackenridge A
Diabet Med. 2024:e15460.
Leggi
Repurposing metformin: a potential off-label indication for ischaemic stroke?
Oo TT
Diabetes Obes Metab. Pub. online 26 Nov 2024.
Leggi
Compounded GLP 1 and Dual GIP/GLP 1 Receptor Agonists: A Statement from the American Diabetes Association
Neumiller JJ, Bajaj M, Bannuru RR, et al.
Diabetes Care. 2024:dci240091.
Leggi
2-fold more cardiovascular disease events decades before type 2 diabetes diagnosis: a nationwide registry study
Gyldenkerne C, Kahlert J, Thrane PG, et al.
J Am Coll Cardiol. 2024;84(23):2251-2259.
Leggi
The relationship of changes in insulin demand and insulin adequacy over the life course
Zhang Y, Tam CHT, Lau ESH, et al.
Diabetologia. Pub. online 29 Nov 2024.
Leggi
Cognitive changes in people with diabetes with lower extremity complications compared to people with diabetes without lower extremity complications: a systematic review and meta-analysis
Karunathilaka N, Parker C, Lazzarini PA, et al.
BMC Endocr Disord. 2024;24(1):258.
Leggi
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
Badve SV, Bilal A, Lee MMY, et al.
Lancet Diabetes Endocrinol. 2024:S2213-8587(24)00271-7.
Leggi